Generic drugs

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic...

Eastman Kodak Co (NYSE: KODK) CEO Jim Continenza said Monday that the company would push ahead with making generic drug ingredients, irrespective of whether it receives government assistance or not, the Wall Street Journal reports. What Happened: “It was put on hold but we are...

The Department of Justice on Tuesday indicted Teva Pharmaceutical Industries Ltd’s (NYSE: TEVA) United States unit for conspiring to fix prices, rig bids, and colluding with other companies to allocate customers for generic drugs. What Happened: The indictment filed in the...

Generic drugmaker Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported a first-quarter earnings beat as the company managed to maintain business continuity, CEO Kare Schultz said on CNBC's "Squawk on the Street." Teva's 'Very Good' Quarter Teva is dedicated to...

Shares of generic and specialty medicines maker Teva Pharmaceutical Industries (NYSE: TEVA) fell more than 9 percent Monday morning in reaction to a lawsuit filed by 44 states. What Happened Teva, along with other global drug companies, is accused of conspiring to inflate the prices of their...

Retail pharmacy chain Rite Aid Corporation (NYSE: RAD) announced a renewal of its contract Wednesday with pharmaceutical distributor McKesson Corporation (NYSE: MCK) through 2029. What Happened McKesson will continue sourcing and offering Rite Aid delivery of branded and generic drugs...

The health care sector, the third-largest sector weight in the S&P 500, is surging. Generic drugmakers have been a source of strength for the group. For example, the VanEck Vectors Generic Drugs ETF (NASDAQ: GNRX) is up 9 percent since the start of 2018 and resides near all-time highs after...

Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...

After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...

Mallinckrodt PLC (NYSE: MNK), a generic specialty pharmaceutical company, said Friday in an 8-K filing it expects to see an up to $500 million benefit from President Donald Trump's tax reform plan. What You Need To Know U.S. government officials passed this week the Tax Cut and Jobs Act and...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...

Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s business has faced multiple pressures, including industry-wide price erosion, a legal battle for possible collusion in generic drug pricing along with a management transition. At the same time, some analysts see the bullish case for owning the...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...

Perrigo Company plc Ordinary Shares (NYSE: PRGO) impressed investors with third-quarter earnings Thursday and issued encouraging guidance that led some of Wall Street's bears to revisit their thesis on the pharmaceutical manufacturer.  The Analyst RBC Capital Markets' Randall...

Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...